跳到正文
Cancer Cell· Yehan Zhang, Shijie Tang, Yi Zhang, Jiahui Liu, Xiaohan Shi, Yikai Li, Yunguang Li, Huan Wang, Chaoliang Zhong, Maoyuan Sun, Wenjie Li, Yiqin Zhu, Weiwei Yang, Yun Zhao, Shiwei Guo, Zhongjun Wu, Lin Wang, Gang Jin, Dong Gao·· 21 天前精选AI 评分63

胰腺癌对 KRASG12D 靶向治疗的敏感性取决于干扰素信号激活

KRASG12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer

AI 导读

Zhang 等的研究显示,胰腺癌对 KRASG12D 靶向治疗的内在耐药与 MYC 持续活跃相关,并伴随干扰素信号受抑。通过 IFN-β 激活干扰素通路可使耐药肿瘤重新敏感,并与 KRAS 抑制剂产生协同作用,提示干扰素信号是可干预的靶点。该摘要未给出样本量、实验模型与效应量。

原文摘要

出版方登记 · OpenAlex

KRAS G12D is a predominant driver in pancreatic cancer, yet the basis of intrinsic resistance to KRAS G12D -targeted therapy remains poorly defined. Integrated genomics, transcriptomics, and proteomics profiling across 242 patient-derived organoids (PDOs) and matched tumor tissues reveals a KRAS G12D -mutant subset intrinsically resistant to KRAS G12D -targeted therapeutics, characterized by marked downregulation of innate immune signaling pathways. Functional validation demonstrates that suppressing interferon signaling in sensitive models induces resistance, whereas activation of interferon signaling, particularly interferon beta (IFN-β), increases sensitivity in resistant models. Combining IFN-β with KRAS inhibitors (MRTX1133, HRS-4642, and RMC-6236) exhibits synergistic antitumor effects in intrinsically resistant pancreatic cancer. Mechanistically, sustained MYC activity is associated with attenuated sensitivity to KRAS inhibition and correlates with repressed interferon signaling, suggesting a potential role in promoting intrinsic resistance. These findings identify interferon signaling as a candidate determinant of KRAS-targeted therapy response and support interferon-based combinations as a potential strategy for intrinsically resistant pancreatic cancer.

页面未能读取全文,以上为出版方登记的摘要;方法与图表见原文

推荐理由

材料指出干扰素信号状态可区分 KRASG12D 靶向治疗的敏感与耐药肿瘤,为联合用药提供可检验的分层依据。

来源:Cancer Cell · cell.com